MLLT3 and intrahepatic cholangiocarcinoma: KMT2A- and MECOM-rearranged cases formed two entities in WHO 2022 but were split into four different entities following ICC separating other partner genes than MLLT3 or GATA2. However, there was no significant difference in OS between KMT2A::MLLT3 and other KMT2A-r cases (Supplementary Fig. S1).